View Cart
My AccountInfectious Disease Diagnostic Solutions
Microbix Phone+1803294983432Microbix Emailcustomer.service@microbix.com
Microbix Logo
Request Catalogue Contact Us
  • Services
    • Custom Vial Filling Services
  • Products
    • Antigens
      • All Antigens
      • Childhood Disease Antigens
      • Dengue Antigens
      • STI Antigens
      • ToRCH Antigens
      • Respiratory Antigens
      • Infectious Disease
    • External Quality Controls (QAPs™)
      • View All
      • Respiratory Viral Panel
      • STI Panel
      • HPV Panel
      • Gastrointestinal Panel
      • Genital Ulcer Panel
      • Vaginal Infections Panel
      • ONBOARDx Kits
      • Proficiency Testing Panel
      • Technical Resources
    • DxTM™ Viral Transport Medium
    • Control Elution Buffer
    • Kinlytic (Urokinase)
  • About
    • Who We Are
    • Quality
    • Board of Directors
    • Our Senior Team
    • Careers
  • Resources
    • White Papers
    • Poster Publication
    • Podcasts
  • Investors
    • News Releases
    • Financial Reports
    • Corporate Presentations
    • Analyst Coverage
    • Corporate Governance
    • Stock Information
Contact Us
Imagine there’s no cervical cancer. It’s easy, if we try.

Imagine there’s no cervical cancer. It’s easy, if we try.

by Aayat Punjabi | May 29, 2025 | Blog, Media Features News Releases, News Releases

Health care is an insatiable driver of  provincial budgets. In Ontario, health expenditures now exceed $87 billion per year and comprise over 40 per cent of overall spending. Such expenses are growing faster than our per capita productivity and show no signs of...
Microbix Reports Results for Q2 Fiscal 2025

Microbix Reports Results for Q2 Fiscal 2025

by Aayat Punjabi | May 15, 2025 | Blog, Media Features News Releases, News Releases

Revenues of $5.3 million, Improved Gross Margin, and Positive Net Income   MISSISSAUGA, CANADA, May 15, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its...
Microbix & Aurevia Introduce Novel EQA Scheme

Microbix & Aurevia Introduce Novel EQA Scheme

by Aayat Punjabi | May 13, 2025 | Blog, Media Features News Releases, News Releases

Pilot Program for Qualifying Clinical Labs to Diagnose Bacterial Vaginosis   MISSISSAUGA, CANADA & HELSINKI, FINLAND, May 13, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and...
Microbix Schedules Release of Results for Q2 Fiscal 2025

Microbix Schedules Release of Results for Q2 Fiscal 2025

by Aayat Punjabi | May 8, 2025 | Blog, Media Features News Releases, News Releases

Results Release and Webinar Discussion on Morning of May 15, 2025   MISSISSAUGA, CANADA, May 8, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the...
Microbix’s Clot-Buster Drug Project Advances

Microbix’s Clot-Buster Drug Project Advances

by Aayat Punjabi | May 5, 2025 | Blog, Media Features News Releases, News Releases

Sequel Pharma Executes Agreement with CDMO for Drug Product Manufacturing   MISSISSAUGA, CANADA, May 5, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and...
Microbix Presenting at the 2025 Bloom Burton Conference

Microbix Presenting at the 2025 Bloom Burton Conference

by Shitika Kulshreshtha | May 1, 2025 | Blog, Media Features News Releases, News Releases

Microbix Presenting at the 2025 Bloom Burton Conference   MISSISSAUGA, ONTARIO, May 1, 2025 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting...
« Older Entries
  • Investors
  • Legal
  • Contact
  • News Releases
  • Accessibility
  • Careers
Microbix Funded By